Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Human DOCK2 Deficiency: Report of a Novel Mutation and Evidence for Neutrophil Dysfunction.

Moens L, Gouwy M, Bosch B, Pastukhov O, Nieto-Patlàn A, Siler U, Bucciol G, Mekahli D, Vermeulen F, Desmet L, Maebe S, Flipts H, Corveleyn A, Moshous D, Philippet P, Tangye SG, Boisson B, Casanova JL, Florkin B, Struyf S, Reichenbach J, Bustamante J, Notarangelo LD, Meyts I.

J Clin Immunol. 2019 Apr;39(3):298-308. doi: 10.1007/s10875-019-00603-w. Epub 2019 Mar 5.

PMID:
30838481
2.

Matrix Metalloproteinase-9-Generated COOH-, but Not NH2-Terminal Fragments of Serum Amyloid A1 Retain Potentiating Activity in Neutrophil Migration to CXCL8, With Loss of Direct Chemotactic and Cytokine-Inducing Capacity.

Gouwy M, De Buck M, Abouelasrar Salama S, Vandooren J, Knoops S, Pörtner N, Vanbrabant L, Berghmans N, Opdenakker G, Proost P, Van Damme J, Struyf S.

Front Immunol. 2018 Jun 4;9:1081. doi: 10.3389/fimmu.2018.01081. eCollection 2018.

3.

The ectoenzyme-side of matrix metalloproteinases (MMPs) makes inflammation by serum amyloid A (SAA) and chemokines go round.

De Buck M, Gouwy M, Struyf S, Opdenakker G, Van Damme J.

Immunol Lett. 2019 Jan;205:1-8. doi: 10.1016/j.imlet.2018.06.001. Epub 2018 Jun 2. Review.

PMID:
29870759
4.

COOH-terminal SAA1 peptides fail to induce chemokines but synergize with CXCL8 and CCL3 to recruit leukocytes via FPR2.

De Buck M, Gouwy M, Berghmans N, Opdenakker G, Proost P, Struyf S, Van Damme J.

Blood. 2018 Jan 25;131(4):439-449. doi: 10.1182/blood-2017-06-788554..

5.

COOH-terminal SAA1 peptides fail to induce chemokines but synergize with CXCL8 and CCL3 to recruit leukocytes via FPR2.

De Buck M, Gouwy M, Berghmans N, Opdenakker G, Proost P, Struyf S, Van Damme J.

Blood. 2017 Dec 4. pii: blood-2017-06-788554. doi: 10.1182/blood-2017-06-788554. [Epub ahead of print]

PMID:
29203586
6.

Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases.

Cockx M, Gouwy M, Van Damme J, Struyf S.

Cell Mol Immunol. 2018 Apr;15(4):312-323. doi: 10.1038/cmi.2017.118. Epub 2017 Nov 27. Review.

7.

Monocytes from patients with Primary Ciliary Dyskinesia show enhanced inflammatory properties and produce higher levels of pro-inflammatory cytokines.

Cockx M, Gouwy M, Ruytinx P, Lodewijckx I, Van Hout A, Knoops S, Pörtner N, Ronsse I, Vanbrabant L, Godding V, De Boeck K, Van Damme J, Boon M, Struyf S.

Sci Rep. 2017 Nov 7;7(1):14657. doi: 10.1038/s41598-017-15027-y.

8.

Neutrophils from Patients with Primary Ciliary Dyskinesia Display Reduced Chemotaxis to CXCR2 Ligands.

Cockx M, Gouwy M, Godding V, De Boeck K, Van Damme J, Boon M, Struyf S.

Front Immunol. 2017 Sep 22;8:1126. doi: 10.3389/fimmu.2017.01126. eCollection 2017.

9.

Relative distribution and biological characterization of CXCL4L1 isoforms in platelets from healthy donors.

Ruytinx P, Janssens R, Berghmans N, Gouwy M, Ronsse I, Liekens S, Proost P, Van Damme J, Struyf S.

Biochem Pharmacol. 2017 Dec 1;145:123-131. doi: 10.1016/j.bcp.2017.08.020. Epub 2017 Aug 30.

PMID:
28859966
10.

Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy.

Abu El-Asrar AM, Struyf S, Mohammad G, Gouwy M, Rytinx P, Siddiquei MM, Hernández C, Alam K, Mousa A, De Hertogh G, Opdenakker G, Simó R.

Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):3189-3201. doi: 10.1167/iovs.16-20993.

PMID:
28654984
11.

Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes.

Janssens R, Mortier A, Boff D, Ruytinx P, Gouwy M, Vantilt B, Larsen O, Daugvilaite V, Rosenkilde MM, Parmentier M, Noppen S, Liekens S, Van Damme J, Struyf S, Teixeira MM, Amaral FA, Proost P.

Biochem Pharmacol. 2017 May 15;132:92-101. doi: 10.1016/j.bcp.2017.03.009. Epub 2017 Mar 18.

PMID:
28322746
12.

CXCL4 and CXCL4L1 Differentially Affect Monocyte Survival and Dendritic Cell Differentiation and Phagocytosis.

Gouwy M, Ruytinx P, Radice E, Claudi F, Van Raemdonck K, Bonecchi R, Locati M, Struyf S.

PLoS One. 2016 Nov 9;11(11):e0166006. doi: 10.1371/journal.pone.0166006. eCollection 2016.

13.

Natural nitration of CXCL12 reduces its signaling capacity and chemotactic activity in vitro and abrogates intra-articular lymphocyte recruitment in vivo.

Janssens R, Mortier A, Boff D, Vanheule V, Gouwy M, Franck C, Larsen O, Rosenkilde MM, Van Damme J, Amaral FA, Teixeira MM, Struyf S, Proost P.

Oncotarget. 2016 Sep 20;7(38):62439-62459. doi: 10.18632/oncotarget.11516.

14.

Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults.

De Buck M, Gouwy M, Wang JM, Van Snick J, Opdenakker G, Struyf S, Van Damme J.

Curr Med Chem. 2016;23(17):1725-55. Review.

15.

Development by Genetic Immunization of Monovalent Antibodies (Nanobodies) Behaving as Antagonists of the Human ChemR23 Receptor.

Peyrassol X, Laeremans T, Gouwy M, Lahura V, Debulpaep M, Van Damme J, Steyaert J, Parmentier M, Langer I.

J Immunol. 2016 Mar 15;196(6):2893-901. doi: 10.4049/jimmunol.1500888. Epub 2016 Feb 10.

16.

The cytokine-serum amyloid A-chemokine network.

De Buck M, Gouwy M, Wang JM, Van Snick J, Proost P, Struyf S, Van Damme J.

Cytokine Growth Factor Rev. 2016 Aug;30:55-69. doi: 10.1016/j.cytogfr.2015.12.010. Epub 2015 Dec 28. Review.

PMID:
26794452
17.

CD26/dipeptidylpeptidase IV-chemokine interactions: double-edged regulation of inflammation and tumor biology.

Mortier A, Gouwy M, Van Damme J, Proost P, Struyf S.

J Leukoc Biol. 2016 Jun;99(6):955-69. doi: 10.1189/jlb.3MR0915-401R. Epub 2016 Jan 7. Review.

PMID:
26744452
18.

Basic chemokine-derived glycosaminoglycan binding peptides exert antiviral properties against dengue virus serotype 2, herpes simplex virus-1 and respiratory syncytial virus.

Vanheule V, Vervaeke P, Mortier A, Noppen S, Gouwy M, Snoeck R, Andrei G, Van Damme J, Liekens S, Proost P.

Biochem Pharmacol. 2016 Jan 15;100:73-85. doi: 10.1016/j.bcp.2015.11.001. Epub 2015 Nov 10.

PMID:
26551597
19.

Serum amyloid A1α induces paracrine IL-8/CXCL8 via TLR2 and directly synergizes with this chemokine via CXCR2 and formyl peptide receptor 2 to recruit neutrophils.

De Buck M, Berghmans N, Pörtner N, Vanbrabant L, Cockx M, Struyf S, Opdenakker G, Proost P, Van Damme J, Gouwy M.

J Leukoc Biol. 2015 Dec;98(6):1049-60. doi: 10.1189/jlb.3A0315-085R. Epub 2015 Aug 21.

PMID:
26297794
20.

Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines.

Gouwy M, De Buck M, Pörtner N, Opdenakker G, Proost P, Struyf S, Van Damme J.

Eur J Immunol. 2015 Jan;45(1):101-12. doi: 10.1002/eji.201444818. Epub 2014 Dec 1.

21.

CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase.

Van Raemdonck K, Gouwy M, Lepers SA, Van Damme J, Struyf S.

Angiogenesis. 2014 Jul;17(3):631-40. doi: 10.1007/s10456-014-9417-6. Epub 2014 Jan 28.

PMID:
24469069
22.

Chemokines and other GPCR ligands synergize in receptor-mediated migration of monocyte-derived immature and mature dendritic cells.

Gouwy M, Struyf S, Leutenez L, Pörtner N, Sozzani S, Van Damme J.

Immunobiology. 2014 Mar;219(3):218-29. doi: 10.1016/j.imbio.2013.10.004. Epub 2013 Oct 14.

PMID:
24268109
23.

Identification and characterization of MIP-1α/CCL3 isoform 2 from bovine serum as a potent monocyte/dendritic cell chemoattractant.

De Buck M, Gouwy M, Proost P, Struyf S, Van Damme J.

Biochem Pharmacol. 2013 Mar 15;85(6):789-97. doi: 10.1016/j.bcp.2012.11.027. Epub 2012 Dec 7.

PMID:
23228695
24.

Possible mechanisms involved in chemokine synergy fine tuning the inflammatory response.

Gouwy M, Schiraldi M, Struyf S, Van Damme J, Uguccioni M.

Immunol Lett. 2012 Jul 30;145(1-2):10-4. doi: 10.1016/j.imlet.2012.04.005. Review.

PMID:
22698178
25.

CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual-tropic (R5/X4) HIV-1 infection.

Gouwy M, Struyf S, Berghmans N, Vanormelingen C, Schols D, Van Damme J.

Eur J Immunol. 2011 Apr;41(4):963-73. doi: 10.1002/eji.201041178. Epub 2011 Mar 7.

26.

Effect of posttranslational processing on the in vitro and in vivo activity of chemokines.

Mortier A, Gouwy M, Van Damme J, Proost P.

Exp Cell Res. 2011 Mar 10;317(5):642-54. doi: 10.1016/j.yexcr.2010.11.016. Epub 2010 Dec 10. Review.

PMID:
21146523
27.

Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.

Struyf S, Salogni L, Burdick MD, Vandercappellen J, Gouwy M, Noppen S, Proost P, Opdenakker G, Parmentier M, Gerard C, Sozzani S, Strieter RM, Van Damme J.

Blood. 2011 Jan 13;117(2):480-8. doi: 10.1182/blood-2009-11-253591. Epub 2010 Oct 27.

28.

Myeloid cells are tunable by a polyanionic polysaccharide derivative and co-determine host rescue from lethal virus infection.

Li S, Starckx S, Martens E, Dillen C, Lamerant-Fayel N, Berghmans N, Gouwy M, van Pel M, Heremans H, Kieda C, Fibbe WE, Billiau A, Van Damme J, Opdenakker G.

J Leukoc Biol. 2010 Nov;88(5):1017-29. doi: 10.1189/jlb.1109724. Epub 2010 Aug 13.

PMID:
20709940
29.

Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine Deiminases (PAD) differently affects its biological activity.

Mortier A, Loos T, Gouwy M, Ronsse I, Van Damme J, Proost P.

J Biol Chem. 2010 Sep 24;285(39):29750-9. doi: 10.1074/jbc.M110.119388. Epub 2010 Jul 14.

30.

CC chemokine ligand-2 synergizes with the nonchemokine G protein-coupled receptor ligand fMLP in monocyte chemotaxis, and it cooperates with the TLR ligand LPS via induction of CXCL8.

Gouwy M, Struyf S, Verbeke H, Put W, Proost P, Opdenakker G, Van Damme J.

J Leukoc Biol. 2009 Sep;86(3):671-80. doi: 10.1189/jlb.1008638. Epub 2009 May 18.

PMID:
19451399
31.

Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects.

Struyf S, Proost P, Vandercappellen J, Dempe S, Noyens B, Nelissen S, Gouwy M, Locati M, Opdenakker G, Dinsart C, Van Damme J.

Eur J Immunol. 2009 Mar;39(3):843-57. doi: 10.1002/eji.200838660.

32.

Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4.

Struyf S, Noppen S, Loos T, Mortier A, Gouwy M, Verbeke H, Huskens D, Luangsay S, Parmentier M, Geboes K, Schols D, Van Damme J, Proost P.

J Immunol. 2009 Jan 1;182(1):666-74.

33.

Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation.

Proost P, Loos T, Mortier A, Schutyser E, Gouwy M, Noppen S, Dillen C, Ronsse I, Conings R, Struyf S, Opdenakker G, Maudgal PC, Van Damme J.

J Exp Med. 2008 Sep 1;205(9):2085-97. doi: 10.1084/jem.20080305. Epub 2008 Aug 18.

34.

Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation.

Loos T, Mortier A, Gouwy M, Ronsse I, Put W, Lenaerts JP, Van Damme J, Proost P.

Blood. 2008 Oct 1;112(7):2648-56. doi: 10.1182/blood-2008-04-149039. Epub 2008 Jul 21.

35.

Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events.

Gouwy M, Struyf S, Noppen S, Schutyser E, Springael JY, Parmentier M, Proost P, Van Damme J.

Mol Pharmacol. 2008 Aug;74(2):485-95. doi: 10.1124/mol.108.045146. Epub 2008 May 9.

PMID:
18469140
36.

Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells.

Vandercappellen J, Noppen S, Verbeke H, Put W, Conings R, Gouwy M, Schutyser E, Proost P, Sciot R, Geboes K, Opdenakker G, Van Damme J, Struyf S.

J Leukoc Biol. 2007 Dec;82(6):1519-30. Epub 2007 Sep 7.

PMID:
17827342
37.

Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells.

Schutyser E, Su Y, Yu Y, Gouwy M, Zaja-Milatovic S, Van Damme J, Richmond A.

Eur Cytokine Netw. 2007 Jun;18(2):59-70. Epub 2007 Jun 26.

38.

Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration.

Proost P, Mortier A, Loos T, Vandercappellen J, Gouwy M, Ronsse I, Schutyser E, Put W, Parmentier M, Struyf S, Van Damme J.

Blood. 2007 Jul 1;110(1):37-44. Epub 2007 Mar 15.

39.

TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis.

Loos T, Dekeyzer L, Struyf S, Schutyser E, Gijsbers K, Gouwy M, Fraeyman A, Put W, Ronsse I, Grillet B, Opdenakker G, Van Damme J, Proost P.

Lab Invest. 2006 Sep;86(9):902-16. Epub 2006 Jul 17.

40.

Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies.

Proost P, Struyf S, Loos T, Gouwy M, Schutyser E, Conings R, Ronsse I, Parmentier M, Grillet B, Opdenakker G, Balzarini J, Van Damme J.

Arthritis Res Ther. 2006;8(4):R107.

41.

Synergy in cytokine and chemokine networks amplifies the inflammatory response.

Gouwy M, Struyf S, Proost P, Van Damme J.

Cytokine Growth Factor Rev. 2005 Dec;16(6):561-80. Epub 2005 Jul 14. Review.

PMID:
16023396
42.

Chemokines synergize in the recruitment of circulating neutrophils into inflamed tissue.

Struyf S, Gouwy M, Dillen C, Proost P, Opdenakker G, Van Damme J.

Eur J Immunol. 2005 May;35(5):1583-91.

43.

GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors.

Gijsbers K, Gouwy M, Struyf S, Wuyts A, Proost P, Opdenakker G, Penninckx F, Ectors N, Geboes K, Van Damme J.

Exp Cell Res. 2005 Feb 15;303(2):331-42.

PMID:
15652347
44.

Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.

Catusse J, Struyf S, Wuyts A, Weyler M, Loos T, Gijsbers K, Gouwy M, Proost P, Van Damme J.

Biochem Pharmacol. 2004 Nov 15;68(10):1947-55.

PMID:
15476666
45.

Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration.

Gouwy M, Struyf S, Catusse J, Proost P, Van Damme J.

J Leukoc Biol. 2004 Jul;76(1):185-94. Epub 2004 Apr 9.

PMID:
15075362
46.

PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia.

Struyf S, Schutyser E, Gouwy M, Gijsbers K, Proost P, Benoit Y, Opdenakker G, Van Damme J, Laureys G.

Am J Pathol. 2003 Nov;163(5):2065-75.

47.
48.

Gene cloning of a new plasma CC chemokine, activating and attracting myeloid cells in synergy with other chemoattractants.

Struyf S, Stoops G, Van Coillie E, Gouwy M, Schutyser E, Lenaerts JP, Fiten P, Van Aelst I, Proost P, Opdenakker G, Van Damme J.

Biochemistry. 2001 Oct 2;40(39):11715-22.

PMID:
11570872

Supplemental Content

Support Center